Merck’s sacituzumab tirumotecan shows overall‑survival benefit in Phase 3 gastro‑esophageal cancer trial

Merck announced that its Phase 3 TroFuse‑015 study of the TROP2‑directed ADC sacituzumab tirumotecan met the primary overall‑survival endpoint in patients with advanced gastro‑esophageal adenocarcinoma who had received at least two prior therapies. The trial enrolled 473 participants and compared the drug to physician’s choice chemotherapy. While overall survival improved, the secondary progression‑free survival endpoint was not achieved. The company said the data will be discussed with regulators and presented at an upcoming medical meeting.

The company indicated that the topline result will be shared with regulatory authorities, suggesting a possible future filing for this indication (the company says it will discuss the data with regulators)【13】. A positive overall‑survival readout could add a new late‑stage asset to Merck’s oncology pipeline and may influence analyst expectations for future revenue streams.

  • 1The TroFuse‑015 trial met its primary overall‑survival endpoint versus treatment of physician’s choice.
  • 2The study enrolled 473 patients with locally advanced unresectable or metastatic gastro‑esophageal adenocarcinoma.
  • 3Patients had received two or more prior lines of systemic therapy.
  • 4The secondary endpoint of progression‑free survival was not met.
  • 5Sacituzumab tirumotecan is licensed from Kelun‑Biotech and is not yet approved for any use.
  • 6Merck plans to present detailed results at an upcoming medical meeting and discuss the data with regulators.

Sources